Profound Medical Corp (PRN)
Toronto Exchange · Canada · prices in CAD · close of 19 Oct 2026
Key indicators
| Last close | CAD 8.250 |
|---|---|
| 52-week range | 6.520 – 12.400 |
| Return, 1 month / 3 months | +0.2% / −14.1% |
| Return, 1 year / 3 years | +6.6% / −35.1% |
| Trend | Below its 200-day average |
| RSI (14) | 43 |
| Volatility (1 year) | 70.7% |
| Worst drawdown (1 year) | -42.3% |
| Average daily value traded | 0.15M CAD |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Profound Medical Corp is a medical device company based in Toronto, Canada. It develops systems that use magnetic resonance imaging together with focused ultrasound to treat tissue inside the body without open surgery. Its main offering, aimed at hospitals and treatment centres, is used by physicians to ablate prostate tissue in patients with prostate disease. The company also works on similar image-guided ultrasound technology for other clinical applications, and it supplies the equipment, software and related support that clinicians need to perform these procedures.
On this site Profound Medical Corp appears as a stock on the Toronto Exchange (Canada), code PRN, with prices in Canadian dollars (CAD). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Profound Medical Corp (PRN) trades on the Toronto Exchange in Canada. It last closed at CAD 8.250 on 19 October 2026.
Its price-based Market X-Ray is 29 out of 100 (a weak price profile), ranking 695 of 868 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 6.6% and over the last three months it fell 14.1%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Toronto Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 29 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -12.3% | ||
| From 52-week high | -31.9% | ||
| Momentum | 33 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -14.1% | ||
| 6-month return | -9.5% | ||
| 12-month return, skipping the last month | 6.3% | ||
| Stability (higher is calmer) | 25 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 70.7% | ||
| Worst drawdown, 1 year (smaller is calmer) | -42.3% | ||
| Liquidity | 31 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.15M CAD | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | −16.1% |
|---|---|
| 1 month | +0.2% |
| 3 months | −14.1% |
| 6 months | −9.5% |
| 1 year | +6.6% |
| 3 years | −35.1% |
| 5 years | – |
Signals
| 50-day / 200-day average | 8.993 / 9.405 |
|---|---|
| Golden / death cross (60 days) | Death, 17 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.596 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Toronto Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.